AbCellera Biologics (ABCL) Gross Profit (2020 - 2025)

AbCellera Biologics has reported Gross Profit for 6 years, with the latest figure at $6.0 million in Q3 2025.

• For the quarter ending Q3 2025, Gross Profit rose 79.39% year-over-year to $6.0 million; the trailing twelve-month figure through Sep 2025 stood at $36.2 million (up 5.22% YoY), and the FY2024 full-year result was $28.8 million, down 24.17% from the prior year.
• Gross Profit for Q3 2025 stood at $6.0 million, down from $14.1 million in the prior quarter.
• The five-year high for Gross Profit was $272.0 million in Q1 2022, with the low at $1.4 million in Q1 2025.
• Historically, Gross Profit has averaged $49.6 million across 5 years, with a median of $14.1 million in 2025.
• Annual changes were most pronounced in 2021 — Gross Profit jumped 4643.2% — and 2023, when it tumbled 96.9%.
• AbCellera Biologics' Gross Profit stood at $137.5 million in 2021, then tumbled by 45.33% to $75.2 million in 2022, then tumbled by 73.05% to $20.3 million in 2023, then declined by 27.51% to $14.7 million in 2024, then tumbled by 58.81% to $6.0 million in 2025.
• The last three Gross Profit figures came in at $6.0 million (Q3 2025), $14.1 million (Q2 2025), and $1.4 million (Q1 2025), per Business Quant data.